Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Offloads Women's Health Business To Two Firms For $1.38Bn

Executive Summary

The generic drug maker signed two deals to divest its women's health business, one with the equity investment firm CVC Capital Partners and the other with Foundation Consumer Healthcare.

You may also be interested in...



Teva Lands A CEO: Can Schultz Replicate Lundbeck Success?

After seven months of uncertainty, Teva has announced a new CEO. But Kåre Schultz, who has won applause for turning around the fortunes of Danish firm Lundbeck over the past two years, faces a daunting turnaround challenge when it comes to the generics behemoth.

Teva To Divest Women's Health, Some Oncology As CEO Search Proceeds

The company is pursuing the sale of global women's health and its oncology and pain businesses in Europe, Interim CEO Yitzhak Peterburg said during the firm's first quarter earnings call.

Wet AMD Market Snapshot: A High-Growth Market Poised For Change

Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.

Topics

Related Companies

UsernamePublicRestriction

Register

GB001758

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel